Latest Infant Formula Market News

Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.

Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.

The a2 Milk Company faced significant supply chain disruptions in its China infant formula segment during late FY26, causing a 14% sales decline in that category. Despite this, overall revenue rose 12% on FY25, supported by strong performances in other product lines and improved margins.

The a2 Milk Company has clinched final Chinese regulatory approval to rebrand infant formula products under its flagship a2™ label, completing a pivotal acquisition step. The company plans to launch these products later in 2026 and is poised to declare a $300 million special dividend.

Australian Dairy Nutritionals has closed the gap on its recent Entitlement Offer by placing 25 million shortfall shares, raising an additional $0.7 million and bringing total proceeds to $1.2 million.

Synlait Milk announces CEO Richard Wyeth's resignation effective end of June, with Acting CEO Leon Fung appointed immediately to steer through ongoing operational challenges.

Synlait Milk has obtained waivers from its syndicated banks on key financial covenants for the quarter ending April 2026, reflecting ongoing operational and market challenges.

Synlait Milk Limited confirms extended product release times and supply chain disruptions following The a2 Milk Company's update on its China infant formula business. The company maintains no FY26 guidance amid persistent industry risks.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

The a2 Milk Company is expanding its strategic partnership with China State Farm to include English label infant milk formula products, starting with a2 Genesis™ in early 2026. This move aims to strengthen distribution control and capitalize on China’s booming infant formula market.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.